
Reader's Digest: UC grad's invention one of 'most trusted brands' in health
UC chemistry graduate George Rieveschl invented Benadryl
Reader's Digest highlighted a University of Cincinnati graduate's invention as part of its top-35 most trusted brands in health and wellness.
Benadryl was named a most-trusted brand for allergy and itch relief by the magazine.
UC chemist George Rieveschl. Photo/UC
It was invented in the 1940s by UC chemistry graduate George Rieveschl. He graduated from UC with a bachelor's degree, a master's degree and a PhD in chemistry. It was at UC where he made his famous discovery of the antihistamine.
He later accepted a position as a faculty member before joining Parke, Davis & Co. to pursue regulatory approval and commercialization of his discovery.
Rieveschl returned to UC in 1970 to serve as vice president of research. He died in 2007 at age 91.
Benadryl is now a product of Pfizer.
UC recognizes distinguished scientific research among faculty each year with an award given in Rieveschl's honor. He is also the namesake of Rieveschl Hall.
Rieveschl initially wanted to be a commercial artist, but enrolled at UC after failing to find a job in that field.
"If I had found an art job back in the 1930s, I would have taken it," Rieveschl told the Cincinnati Post. "It seemed like bad luck at the time, but it ended up working pretty well."
See the rest of Reader's Digest's most-trusted brands in health and wellness.
Related Stories
How Publix’s arrival to the Tri-State could impact shoppers
March 25, 2025
Eunjee Kwon, PhD, assistant professor of real estate in the Lindner College of Business, spoke with Fox 19 about the expansion of Publix, a Florida-based grocery chain, in the Tri-State.
President Pinto shares search update for executive vice...
March 25, 2025
President Neville Pinto shares search update for executive vice president for academic affairs and provost
Breakthrough cancer trial offers hope for pancreatic cancer...
March 25, 2025
Local 12 highlighted University of Cincinnati Cancer Center researcher Davendra Sohal and patient Ron Solomon who is enrolled in a pancreatic cancer trial targeting a genetic mutation called KRAS.